Arcellx

Arcellx's Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) demonstrated a 97% overall response rate and 68% complete response rate in 117 patients with relapsed/refractory multiple myeloma.

The CAR-T cell therapy industry has raised over $141.2 billion through various financing mechanisms, with estimates suggesting total industry funding could reach $281.7 billion when including undisclosed deals.

Bristol Myers Squibb has agreed to acquire 2seventy bio for $286 million, ending the profit-sharing arrangement for the BCMA-targeted CAR-T therapy Abecma used in multiple myeloma treatment.

The CAR T-cell therapy pipeline has experienced significant growth, with over 180 companies actively developing more than 200 innovative cell therapy candidates across various stages of clinical development.

Anitocabtagene autoleucel (anito-cel) demonstrates a high overall response rate of 97% in heavily pretreated, high-risk relapsed or refractory multiple myeloma patients.

• A comprehensive review of global clinical trials for relapsed multiple myeloma (R/R MM) reveals key trends in trial locations, phases, and sponsor types. • The analysis identifies prominent drugs under investigation and highlights recent clinical trial news, including updates from ASH 2024 and other major meetings. • The review emphasizes the importance of understanding trial enrollment trends and success rates to inform business strategies and identify key opportunities in the R/R MM therapeutics market. • Recent data showcases promising results for novel combinations and CAR-T cell therapies, suggesting potential breakthroughs in treating R/R MM.

• Carvykti (ciltacabtagene autoleucel) demonstrated an 89% minimal residual disease (MRD) negativity rate in patients with relapsed or refractory multiple myeloma after nearly three years of follow-up. • The MRD negativity rate with Carvykti was more than double that of standard therapies, showing a highly statistically significant treatment effect (p < 0.0001). • A prior data release showed Carvykti significantly increased overall survival and reduced the risk of death by 45% compared to standard therapies. • While Carvykti shows promise, emerging BCMA CAR-T therapies with potentially improved safety profiles may challenge its market share.

• Arcellx's anito-cel demonstrated a 97% overall response rate and a 62% complete response rate in patients with relapsed or refractory multiple myeloma. • The iMMagine-1 Phase 2 study showed 93.1% of evaluable patients achieved minimal residual disease negativity, indicating deep remission. • No delayed neurotoxicities were observed, highlighting a favorable safety profile compared to other CAR-T therapies. • The Phase 1 study of anito-cel showed a 30.2-month median progression-free survival, suggesting long-term efficacy.

Arlocabtagene autoleucel (arlo-cel) demonstrated a 91% overall response rate in heavily pretreated multiple myeloma patients, regardless of high-risk cytogenetics or prior BCMA-directed therapy.

• Kite, a Gilead Company, will present 18 presentations at ASH 2024, showcasing its CAR T-cell therapy portfolio across various blood cancers. • Anito-cel, co-developed with Arcellx, demonstrates durable responses in relapsed/refractory multiple myeloma patients, with a 30.2-month median progression-free survival in Phase 1. • Yescarta shows superior overall survival versus standard therapy in relapsed/refractory large B-cell lymphoma, supported by the largest real-world analysis of CAR T for second-line therapy. • Tecartus demonstrates durable responses in relapsed/refractory mantle cell lymphoma, with five-year outcomes from ZUMA-2 highlighting unprecedented efficacy three years post-approval.